Josh D. Woolley, MD, PhD

Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.

Woolley discusses why an active placebo's own therapeutic effects complicate psilocybin trial blinding and outlines next steps for testing UMBRAA.

Woolley separates intoxication from delirium and defends aggressive masking instead of a shift to comparative efficacy trial designs.

Josh Woolley, MD, PhD, says active placebos fail to mask high-dose psilocybin and propose combining drug classes with authorized incomplete disclosure.

In his paper, Josh D. Woolley, MD, PhD, proposes multidrug active placebos and limited disclosure to finally mask high-dose psilocybin trials.